Retension Pharmaceuticals prices upsized $45M NASDAQ IPO
Retension Pharmaceuticals, Inc. (NASDAQ: RTSN) priced its initial public offering on October 14, 2026, raising $45 million. The clinical-stage biopharma focuses on neurodegenerative diseases. The offering was upsized and priced at the high end of the range, with H.C. Wainwright & Co. among the underwriters.
51CFO view：For Chinese biotech firms targeting US IPOs: RTSN highlights SEC’s heightened scrutiny of value proposition disclosures. CFOs must lead development of defensible R&D capitalization policies, milestone accounting frameworks, and FDA engagement impact assumptions in the S-1—requiring hands-on ASC 730/985 experience and regulatory dialogue fluency.
Retension Pharmaceuticals, Inc. (NASDAQ: RTSN) priced its initial public offering on October 14, 2026, raising $45 million. The clinical-stage biopharma focuses on neurodegenerative diseases. The offering was upsized and priced at the high end of the range, with H.C. Wainwright & Co. among the underwriters.
Source：Google News · 美股 IPO
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
What to do 18 months before filing
Financial readiness: audit basis, internal control, equity restatement.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →